May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Bevacizumab (Avastin) and Ranibizumab (Lucentis) Enhance the Permeability of Cultured Retinal Pigment Epithelium, but Not in the Presence of Triamcinolone Acetonide
Author Affiliations & Notes
  • Y. Miura
    Department of Ophthalmology, University of Kiel, Kiel, Germany
  • A. Klettner
    Department of Ophthalmology, University of Kiel, Kiel, Germany
  • J. Roider
    Department of Ophthalmology, University of Kiel, Kiel, Germany
  • Footnotes
    Commercial Relationships  Y. Miura, None; A. Klettner, None; J. Roider, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 486. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Miura, A. Klettner, J. Roider; Bevacizumab (Avastin) and Ranibizumab (Lucentis) Enhance the Permeability of Cultured Retinal Pigment Epithelium, but Not in the Presence of Triamcinolone Acetonide. Invest. Ophthalmol. Vis. Sci. 2008;49(13):486. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Intravitreal anti-vascular endothelial growth factor (VEGF) treatment, such as with bevacizumab or ranibizumab, has been prevailed rapidly as a promising therapy for choroidal neovascularisation in age-related macular degeneration (AMD). However, there are only very limited data about their effect on normal eye tissue. For a good prognosis, not only the involution of choroidal neovasucularisaion but also the stability of the neighboring retinal pigment epithelium (RPE) is needed. We investigated the effect of bevacizumab and ranibizumab on the permeability of RPE in vitro.

Methods: : RPE cells were isolated from enucleated porcine eyes. The second passage was cultured on 6-well membrane insert for about 4 weeks after confluence. Bevacizumab (0.0625mg/ml) or ranibizumab (0.05mg/ml) was added in the medium of the upper chamber, and 24 hours later the medium in both upper and lower chamber were replaced with fresh medium, containing fluoresceine isothiocyanate (FITC)-dextran in the upper medium. In some chambers, 10-5M of triamcinolone acetonide was added. After 5 hours, the medium from the lower chamber was collected and the fluorescence intensity was measured with a spectrofluorometer.

Results: : Bevacizumab and ranibizumab increased the permeability of the fluorescent label after 24 hours of stimulation. Even after completely removing these agents, the permeability increased significantly in avastin-treated cells up to the eighth day. On the other hand, lucentis-treated cells showed higher permeability only on the first day and, at the third day until eighth day, permeability was normal. Triamcinolone acetonide inhibited the permeability increase by these anti-VEGF agents significantly.

Conclusions: : Bevacizumab and ranibizumab might cause the loss of junctional integrity of cultured RPE cells. Especially bevacizumab seems to cause the prolonged increase of permeability. Since triamcinolone significantly inhibited this effect, the combined therapy with Triamcinolone might be beneficial for the stability of RPE permeability after anti-VEGF treatment.

Keywords: retinal pigment epithelium • age-related macular degeneration • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×